IlluminaILMN
Recorded

Illumina Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Tycho PetersonAnalyst

Okay. We're going to kick it off. I'm Tycho Peterson from the Life Science team. It's my pleasure to have Illumina. Welcome, Ankur. Yeah. Thanks, Tycho.

Tycho PetersonAnalyst

Maybe just set the stage here, just some of the coming out of the third quarter, some of the gives and takes, and how you're thinking about trends heading into next year.

Ankur DhingraCFO

Yeah, sure. As a reminder, very pleased with how Q3 overall panned out for us. As a reminder for everyone, we laid out a framework for Illumina a couple years ago in 2024, in terms of returning the company towards high single-digit growth. We've made tremendous progress towards that, despite different changes that happened in the end markets for us. 2026 is a step there, where we are steadily in the mid-single-digit growth over the quarters, as well as in our guide for Q4. Q3 was the right step in that business as well. Some highlights, again, our placements on the instrumentation remain very strong. We've said our clinical business is where a lot of this upside demand has been coming from, especially in the U.S., as well as a little bit outside the U.S. as well on the clinical markets.

Ankur DhingraCFO

The consumables growth has held steady, in line with both the increasing install base, as well as where it can go going forward. We have made a lot of progress in building up our multiomics as well as our BioInsight portfolio, in line with what we have said in 2027, where we continue to expect to see the increased contribution into revenue growth from that. Lastly, equally importantly, made 25% op margin during the quarter, still guiding to 25-ish percent in Q4 as well. So for the second half to be at 25% operating margin is also kind of good milestone in our trajectory of getting to the 500 basis point margin expansion in our core businesses over that period of time. All in all, a great quarter.

Tycho PetersonAnalyst

You mentioned the strong instrument placements, over 80 X placements. I think one of the things people are trying to understand a little bit more is just the relationship between placements, instrument revenues, how you think about kind of the long-term returns on some of these clinical placements that are obviously going to be used more heavily than research. So talk a little bit about some of the gives and takes on these strong instruments that you have seen.

Ankur DhingraCFO

Yeah. We are very pleased with where the instrument placements have been, especially over the last four quarters. I think we mentioned that we have now had more placements in these quarters, four quarters, than we had during the first year of launch, which is pretty unique. A lot of that has to do with both, the two things. One, just the underlying clinical demand being very strong, but also very importantly, we started laying out a framework for what NovaSeq X could do, and the additional throughput and the value our customers can get out of NovaSeq X over an extended period of time, which is allowing our customers to make a lot of long-term bets on the platform, especially around the clinical validation. In terms of consumables growth, well, that is the formula.

Ankur DhingraCFO

More placements over a period of time gives us even more confidence about the increasing consumables growth, the larger the install base. Yeah. You look at our consumables growth, it is being driven by clinical, it is being driven by X. I think a question that always comes up in that, in the formula that you are probably referring to, is the pull-through dynamics there. What everyone has seen and what we have seen over the period of time is that our clinical customers, when they buy boxes, their pace at which they get to peak pull-through usually takes longer than what the research customers typically do. Our clinical customers run through validation, and additionally, a lot of their pull-through also works as the on-market test or the clinical trials, whatever they are adding the capacity for. As that ramps, we see the pull-through pick up accordingly.

Ankur DhingraCFO

That dynamic is playing out as well, because a lot of our above-average placements have largely been on the clinical side.

Tycho PetersonAnalyst

I think one of the things you've done a good job is highlighting just U.S. clinical consumable growth has been over 20%.

Tycho PetersonAnalyst

That's right. Any reason that you don't view that as sustainable, just given what you're seeing in the market today on the U.S. clinical side?

Ankur DhingraCFO

Look, if you look at the U.S. end markets, largely driven by some of our largest customers who have been very public about what their plans and ambitions are. You look at the drivers of growth in that space, the core therapy selection has held up quite well. Then the MRD and the upcoming MCED are layering in additional growth within that market. If I look at what our customers are saying and what their ambitions are, if they continue to execute to those levels of ambition, then that is good for us, right, in terms of our ability to sustain the growth rate in those markets consistent with where our customers are going. That is the dynamic in that space. We also look at, because we talk about U.S. a lot, and given the amount of focus those companies get, our business is international.

Ankur DhingraCFO

One of the dynamics that we also very closely watch is the evidence generation. The clinical adoption historically has always been led by the U.S., right. It is U.S. where the innovation happens first, the at-risk investments happen first, and over a period of time, as either clinical or on-market evidence gets generated, the adoption in rest of the world starts, usually in Europe and some of the wealthier Asian countries, and then more broadly. So both in Europe and the rest of the world, the MRD as well as early detection is still a tailwind in the future. We have not started seeing much of a tailwind in those outer regions out of those two oncology dynamics yet.

Tycho PetersonAnalyst

How about on the, just the reimbursement front internationally. I know there has been some pressure in parts of Europe, Germany, France. I guess as you think about some of these growing categories and maybe the scrutiny around reimbursement, does that become a headwind internationally on some of these newer categories too?

Ankur DhingraCFO

Yeah, I think we mentioned about some changes in Germany recently. In the grand scheme of things for our size of business, the impact was relatively small coming from the reimbursement there. The way we think about reimbursement overall dynamics is still in the end about clinical utility. The more the evidence gets stronger around the clinical utility of our tests, their ability to say, "We are able to diagnose the disease sooner," that is the primary factor for managing the reimbursement. For us, the puts and takes are always around the right level of reimbursement as well as right level of adoption, right. Higher the adoption, higher the ability of many countries being able to afford these tests has always been part of our business case of saying, "We want to democratize use of NGS.

Ankur DhingraCFO

We want it to be much more broadly adopted across the entire world. Wherever pricing eventually lands, if the adoption is wider, it is good for our business.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day